Nice to see prospective validation of pre-treatment ctDNA burden as prognostic in EWS. 💚💙🧪🩸🩺

Circulating Tumor DNA Profiling Defines Risk Classification in Patients With Ewing Sarcoma: A Report from the Children’s Oncology Group and the LEOPARD Study. Read the full article. bit.ly/4y17Ehz

In a trial of a blood-based multicancer early-detection test added to usual care, the incidence of stage III or IV cancer after three rounds of screening did not differ significantly from that with usual care alone. Full NHS-Galleri trial results: nej.md/4xRZN5L Editorial: A Step in the Search for the Elusive Holy Grail of Early Detection of Cancer nej.md/4cK3UIy

📝 #JAMAReview: #LiquidBiopsy using circulating #tumor #DNA can help guide care in #Cancer by identifying gene variants associated with treatment selection, monitoring treatment response, and detecting minimal residual disease after therapy. Detectable circulating tumor DNA after curative-intent treatment was associated with recurrence and poorer survival across multiple cancer settings, often before progression was evident on imaging. ja.ma/4dFgtVU

PEGASUS trial: Can adjuvant treatment after surgery for high-risk stage II–III colon cancer be personalized according to ctDNA status? 🔹 ctDNA-negative: no oxaliplatin → 6 months of capecitabine 🔹 ctDNA-positive: 3 months of CAPOX → switched to FOLFIRI if ctDNA remained positive. The primary aim was to determine whether oxaliplatin could be safely omitted in ctDNA-negative patients. The target 2-year relapse-free rate was ≥92%; the observed rate was 88%, so the primary endpoint was not met. Nevertheless, 3-year DFS was 82.8% in ctDNA-negative vs 58.4% in ctDNA-positive patients. ctDNA is clearly a strong prognostic marker, but this study does not yet establish that oxaliplatin can be safely omitted solely on the basis of a negative ctDNA result. nature.com/articles/s43018-0…

Positive phase 3 data for adjuvant pembro +/- personalized mRNA-based neoantigen vaccine for melanoma just announced by Merck and Moderna. Welcome to the future! merck.com/news/merck-and-mod…

Among patients with early #TripleNegativeBreastCancer, tissue-free #ctDNA detection during molecular residual disease surveillance was strongly prognostic for recurrence and supported testing when tumor tissue was unavailable. ja.ma/4g8HyBp

According to new research, ctDNA clearance and MRD status may help identify which patients with resectable non-small cell lung cancer get the greatest benefit from immunotherapy given before and after surgery. spr.ly/6019B1OZlB #EndCancer

Wrapping up #ASCO26 with @HeadNeckMD delivering phase 1 interim analysis results on emiltatug ledadotin, a targeted antibody-drug conjugate being studied for patients with aggressive adenoid cystic carcinoma.

Tune-in tomorrow, June 1st for our #HNSCC KOL event at #ASCO26—updated Phase 1/2 data for CRB-701 including clinical response durability and subgroup analysis, with expert discussion from @AriRosenbergMD, @HeadNeckMD and @CesarAPerezMD. Register here: bit.ly/3QS9MHC

Ten years ago, liquid biopsy in HPV+ cancer was a hypothesis. Today, TTMV®-HPV DNA surveillance has been validated across multiple prospective studies, expert consensus recommendations, and a systematic meta-analysis with pooled sensitivity of 86% and specificity of 96% across 12 studies and more than 1,300 patients. [1] That’s what a decade of focused research looks like. #NationalCancerResearchMonth #NavDx #Naveris #ctDNA #ctHPVDNA #MRD #LiquidBiopsy #CancerSurveillance #Oncology #Biotech #HPV #HPVcancer #HeadAndNeckCancer #HNCancer #OPSCC #AnalCancer #ASCC 1. Campo F et al. J Exp Clin Cancer Res. 2024. doi.org/10.1186/s13046-024-0… .

Sharing the results of ReACT 1.0 in @NatureComms -- the first study to use HPV ctDNA to guide CRT de-escalation in higher risk HPV+ OPC. ctDNA metrics may improve risk stratification. Grateful to our coauthors. @Naveris_inc @DanaFarberNews @jdschoenfeld1 nature.com/articles/s41467-0…

We’re pleased to announce that the U.S. FDA has granted Fast Track designation to first-in-class, small molecule MYB mRNA degrader, REM-422, for the treatment of recurrent, metastatic, or unresectable ACC. bit.ly/4rC0UT5 #REM422 #AdenoidCysticCarcinoma

Could we use ctDNA to de-escalate therapies when treating Head and Neck cancers - #HNCA26 annual meeting - that’s what @HeadNeckMD of @DanaFarberNews will be discussing soon - @UCCancerCenter @AriRosenbergMD @ajuloorimd @UChicagoMed

Up to 25% of patients with HPV+ oropharyngeal cancer will experience recurrence. Currently, most recurrences are first reported by the patient and most recurrences are found later than need be. To help identify patients with recurrent disease sooner, when they are asymptomatic and tumor burdens are more likely lowest, circulating tumor HPV DNA (ctHPVDNA) tests, like the NavDx® test, should be added to clinical pathways or protocols. This is one of the notable recommendations from the California Head & Neck Consortium in their recently published consensus paper. 33 leading multidisciplinary experts from 15 institutions also established: 🔹Serial testing is recommended in years 1 through 5, in conjunction with routine surveillance visits 🔹ctHPVDNA provides higher specificity and sensitivity, and improves time to detection of cancer recurrence than standard-of-care methods  🔹Detection of molecular recurrence should prompt more frequent imaging 🔹Serial testing should be performed, rather than testing at a single post-treatment time point These findings support what thousands of clinicians throughout the U.S. are already seeing in their practices: Routine post-treatment monitoring of patients with HPV+ oropharyngeal cancer using the NavDx test can identify cancer recurrence earlier than symptoms or imaging alone.  Access the full publication here: bit.ly/3MrPgeG  #RadiationOncology #MedicalOncology #ENT #OropharyngealCancer #NavDxTesting

Standard-of-care surveillance modalities for HPV+ oropharyngeal squamous cell carcinoma (OPSCC) have not changed in many years. As many as 25% of patients will experience recurrence, but standard modalities will fail to detect the majority of recurrences, especially in asymptomatic patients. Fiberoptic laryngoscopy identifies recurrence only 0.3% to 2% of the time (1,2), and advanced imaging such as PET/CT is not part of recommended surveillance guidelines.  Incorporating the NavDx® test (or a similar tool) into routine surveillance, as recently recommended by the California Head and Neck Consortium (bit.ly/3MrPgeG), can provide a highly specific, highly sensitive, and non-invasive way to get deeper insight into your patients’ cancer status when used as a complement to standard methods. NavDx testing’s high PPV can reduce the risk of unnecessary invasive procedures, while its high NPV can offer patients greater confidence in their response to treatment and current disease management. Contact us today to learn more! bit.ly/49DJzT5  #Naveris #NavDx #oncology #clinicaldata #healthcare #hpvcancer #hncancer #cancersurveillancesolution  1. Kothari P, et al. doi: 10.1007/s00405-010-1461-2. 2. Boysen M, et al. doi: 10.1016/s0959-8049(05)80068-1.

📢Excited for this case-based multidisciplinary meeting @UCCancerCenter discussing innovation and treatment optimization for #hncsm!🩺🧬🔬🩻 @HeadNeckMD @ajuloorimd @williamgaomd @your_hemoncdoc @DrUppaluri @NouraChoudhury @lab_pearson @DrJLorch @DanielOlsonMD @headandneckdoc

The California Head & Neck Consortium released the first multidisciplinary consensus recommendations on the use of circulating tumor HPV DNA in HPV+ oropharyngeal carcinoma. The panel of 33 experts representing 15 institutions reached strong consensus that a tool like the NavDx® test should be incorporated into routine surveillance. The consensus recommendations also included: Using an option like the NavDx test improves time to recurrence detection vs. conventional surveillance tools, but should supplement these methods, not reduce or replace them. The recommended time for a patient’s first post-treatment test is 3 months. Serial testing should be performed in conjunction with conventional surveillance every 3 months in the first 2 years post-treatment and every 6 months in years 3-5. For patients with a single positive post-treatment test where no clinical or radiographic evidence of disease is present, the best time to repeat the test is in one month. Earlier molecular detection of locoregional or oligometastatic disease should improve outcomes. These recommendations reinforce real-world clinical validation and value of new technologies like the NavDx test in earlier detection of molecular residual disease and recurrence of HPV+ oropharyngeal cancer. Access the full publication here: bit.ly/3MrPgeG  #ctHPVDNA #HeadAndNeckCancer #Oncology #MRD #NavDx #CancerSurveillance #hncancer

Head and neck #cancer is the seventh most common cancer worldwide. This JAMA Review summarizes the epidemiology, clinical presentation, diagnosis, and treatment of head and neck squamous cell carcinomas (#HNSCC) of the upper aerodigestive tract. ja.ma/4qhWyAn

Dr. Glenn Hanna (@HeadNeckMD), Director of the CCTI at @DanaFarber & Associate Prof. of Medicine at @harvardmed, comments on the promising data on elraglusib as a treatment and GSK-3β as a therapeutic target for metastatic salivary gland cancer. bit.ly/4pC694W $ACTU